Literature DB >> 15496149

Expression of somatostatin in the adult and developing mouse kidney.

Carlton M Bates1, Heather Kegg, Sandy Grady.   

Abstract

BACKGROUND: Somatostatin (somatotropin release inhibiting factor) (SRIF) has potent antiproliferative and antisecretory actions. In the adult kidney, somatostatin alters renal blood flow, ion transport, and water permeability. While some evidence suggests that SRIF may be produced by adult kidney tubular cells, the specific tubules generating SRIF are unknown. Somatostatin has also been detected in a variety of embryonic tissues, although it has not been described in the developing kidney. Our objective was to determine the expression pattern of SRIF in both the adult and embryonic mouse kidney.
METHODS: We performed reverse transcriptase-polymerase chain reaction (RT-PCR) and immunofluorescence for SRIF in developing and adult mouse kidney tissues. We localized SRIF by dual or serial labeling immunofluorescence with specific markers.
RESULTS: Somatostatin mRNA was present in kidneys throughout embryogenesis and into adulthood. Starting at embryonic day (E) 12.5, SRIF was strongly expressed at the interface of the metanephric mesenchymal cells and the basolateral surfaces of ureteric bud trunks. Starting at E16.5, the staining at the interface was confined to the peripheral ureteric bud trunks and the clefts of newly dividing ureteric bud ampullae. In older embryos, SRIF also appeared in medullary tubules that appeared to be maturing thin descending limbs of Henle. In the adult kidney, SRIF proteins localized exclusively to medullary thin descending limbs of the Henle loop.
CONCLUSION: In embryonic kidneys, SRIF is expressed first at the interface of the metanephric mesenchyme and basolateral ureteric bud and later in maturing thin descending limbs of Henle. Expression in the thin descending limb persists in the adult kidney.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15496149     DOI: 10.1111/j.1523-1755.2004.00953.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  7 in total

1.  Cubilin and megalin in radiation-induced renal injury with labelled somatostatin analogues: are we just dealing with the kidney?

Authors:  R Moncayo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10       Impact factor: 9.236

Review 2.  Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2013-12-12       Impact factor: 10.121

Review 3.  Cyclic AMP-mediated cyst expansion.

Authors:  Darren P Wallace
Journal:  Biochim Biophys Acta       Date:  2010-11-28

Review 4.  Heterotrimeric G protein signaling in polycystic kidney disease.

Authors:  Taketsugu Hama; Frank Park
Journal:  Physiol Genomics       Date:  2016-05-13       Impact factor: 3.107

5.  Expression of somatostatin and somatostatin receptor subtypes 1-5 in human normal and diseased kidney.

Authors:  Sunil Bhandari; Neil Watson; Ervine Long; Steve Sharpe; Wenwen Zhong; Shang-Zhong Xu; Stephen L Atkin
Journal:  J Histochem Cytochem       Date:  2008-04-28       Impact factor: 2.479

6.  Pancreatic polypeptide inhibits somatostatin secretion.

Authors:  Wook Kim; Jennifer L Fiori; Yu-Kyong Shin; Eitan Okun; Jung Seok Kim; Peter R Rapp; Josephine M Egan
Journal:  FEBS Lett       Date:  2014-07-11       Impact factor: 4.124

7.  Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.

Authors:  Marie C Hogan; Julie A Chamberlin; Lisa E Vaughan; Angela L Waits; Carly Banks; Kathleen Leistikow; Troy Oftsie; Chuck Madsen; Marie Edwards; James Glockner; Walter K Kremers; Peter C Harris; Nicholas F LaRusso; Vicente E Torres; Tatyana V Masyuk
Journal:  Clin J Am Soc Nephrol       Date:  2020-08-25       Impact factor: 8.237

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.